Reduced incidence and frequency of hypoglycaemia in an integrated analysis of pooled data from clinical trials of subjects with type 2 diabetes using prandial inhaled Technosphere insulin

被引：0
|
作者：
Lorber, D. [1 ]
Howard, C. [1 ]
Ren, H. [1 ]
Rossiter, A. [1 ]
Boss, A. [1 ]
机构：
[1] Diabet Care & Informat Ctr New York, Flushing, NY USA
来源：
DIABETOLOGIA | 2009年 / 52卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
918
引用
收藏
页码：S360 / S360
页数：1
相关论文
共 50 条
  • [1] Reduced incidence and frequency of hypoglycaemia in an integrated analysis of pooled data from clinical trials of subjects with type 1 diabetes using prandial inhaled Technosphere insulin
    Howard, C.
    Ren, H.
    Rossiter, A.
    Boss, A.
    DIABETOLOGIA, 2009, 52 : S386 - S387
  • [2] Markedly reduced postprandial glucose excursions through inhaled technosphere/insulin in comparison to SC injected regular insulin in subjects with type 2 diabetes
    Boss, AH
    Cheatham, WW
    Rave, K
    Heise, T
    DIABETOLOGIA, 2005, 48 : A296 - A297
  • [3] Risk factors and prediction of hypoglycaemia using the Hypo-RESOLVE cohort: a secondary analysis of pooled data from insulin clinical trials
    Mellor, Joseph
    Kuznetsov, Dmitry
    Heller, Simon
    Gall, Mari-Anne
    Rosilio, Myriam
    Amiel, Stephanie A.
    Ibberson, Mark
    Mcgurnaghan, Stuart
    Blackbourn, Luke
    Berthon, William
    Salem, Adel
    Qu, Yongming
    Mccrimmon, Rory J.
    de Galan, Bastiaan E.
    Pedersen-Bjergaard, Ulrik
    Leaviss, Joanna
    Mckeigue, Paul M.
    Colhoun, Helen M.
    DIABETOLOGIA, 2024, 67 (08) : 1588 - 1601
  • [4] Lower risk of hypoglycaemia with insulin detemir versus NPH insulin in elderly persons with type 2 diabetes: a pooled analysis of phase 3 trials
    Garber, AJ
    Kim, H
    Santiago, O
    DIABETOLOGIA, 2005, 48 : A294 - A294
  • [5] Estimating risk of consequences following hypoglycaemia exposure using the Hypo-RESOLVE cohort: a secondary analysis of pooled data from insulin clinical trials
    Mellor, Joseph
    Kuznetsov, Dmitry
    Heller, Simon
    Gall, Mari-Anne
    Rosilio, Myriam
    Amiel, Stephanie A.
    Ibberson, Mark
    Mc Gurnaghan, Stuart
    Blackbourn, Luke
    Berthon, William
    Salem, Adel
    Qu, Yongming
    Mccrimmon, Rory J.
    de Galan, Bastiaan E.
    Pedersen-Bjergaard, Ulrik
    Leaviss, Joanna
    Mc Keigue, Paul M.
    Colhoun, Helen M.
    DIABETOLOGIA, 2024, 67 (10) : 2210 - 2224
  • [6] Pooled analysis of clinical trials investigating the pharmacokinetics (PK) of ultra-rapid insulin BioChaperone Lispro vs lispro in subjects with type 1 and type 2 diabetes
    Heise, T.
    Ranson, A.
    Gaudier, M.
    Soula, O.
    Alluis, B.
    Zijlstra, E.
    Glezer, S.
    Meiffren, G.
    DIABETOLOGIA, 2018, 61 : S400 - S400
  • [7] Dapagliflozin in patients with type 2 diabetes mellitus: A pooled analysis of safety data from phase IIb/III clinical trials
    Jabbour, Serge
    Seufert, Jochen
    Scheen, Andre
    Bailey, Clifford J.
    Karup, Cathrina
    Langkilde, Anna M.
    DIABETES OBESITY & METABOLISM, 2018, 20 (03): : 620 - 628
  • [8] Cardiovascular safety assessment of pramlintide in type 2 diabetes: results from a pooled analysis of five clinical trials
    Kathrin Herrmann
    Ming Zhou
    Andrew Wang
    Tjerk W. A. de Bruin
    Clinical Diabetes and Endocrinology, 2 (1):
  • [9] Cardiovascular Safety of Exenatide BID: An Integrated Analysis from Long-Term Controlled Clinical Trials in Subjects with Type 2 Diabetes
    Shen, Larry
    Han, Jenny
    Yushmanova, Irina
    Bruce, Simon
    Porter, Lisa
    DIABETES, 2009, 58 : A96 - A97
  • [10] Incidence of Urinary Tract Infection in Subjects with Type 2 Diabetes. Experience from Adverse Event Reporting in Diabetes Clinical Trials
    Hammar, Niklas
    Farahmand, Bahman
    Andersson, Susan
    Joelson, Svante
    Gran, Mikael
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2009, 18 : S41 - S42
12345